Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: the Early Rapid ReversAl of platelet thromboSis with intra

@article{Berger2009SafetyAF,
  title={Safety and feasibility of adjunctive antiplatelet therapy with intravenous elinogrel, a direct-acting and reversible P2Y12 ADP-receptor antagonist, before primary percutaneous intervention in patients with ST-elevation myocardial infarction: the Early Rapid ReversAl of platelet thromboSis with intra},
  author={Jeffrey S. Berger and Matthew T. Roe and C Michael Gibson and Rakhi Kilaru and Cynthia L Green and Laura Melton and James D Blankenship and David Christopher Metzger and Christopher B. Granger and Daniel D. Gretler and Cindy Lee Grines and Kurt Huber and Uwe Zeymer and Paweł E. Buszman and Robert A. Harrington and Paul Wayne Armstrong},
  journal={American heart journal},
  year={2009},
  volume={158 6},
  pages={998-1004.e1}
}
BACKGROUND Inhibition of the P2Y12 ADP-receptor with oral antiplatelet agents given to patients undergoing primary percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI) is associated with improved outcomes, but this strategy is limited by the time required for maximal antiplatelet effect after administration. We examined the safety and tolerability of a novel, direct-acting, reversible, intravenous P2Y12 ADP-receptor antagonist, elinogrel, versus placebo when… CONTINUE READING